Back to Browse Journals » Pharmacogenomics and Personalized Medicine » Volume 4

A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross

Authors Gelinas R, Chesler EJ, Vasconcelos D, Miller DR, Yuan Y, Wang K, Galas D

Published Date July 2011 Volume 2011:4 Pages 35—45

DOI http://dx.doi.org/10.2147/PGPM.S22475

Published 4 July 2011

Richard Gelinas1,3, Elissa J Chesler2, Daphne Vasconcelos1, Darla R Miller2, Yue Yuan3, Kai Wang3, David Galas1,3
1Battelle Memorial Institute, Columbus, OH; 2Oak Ridge National Laboratory, Oak Ridge, TN; 3Institute for Systems Biology, Seattle, WA, USA

Abstract: The antineoplastic drug bleomycin leads to the side effect of pulmonary fibrosis in both humans and mice. We challenged genetically diverse inbred lines of mice from the Collaborative Cross with bleomycin to determine the heritability of this phenotype. Sibling pairs of mice from 40 lines were treated with bleomycin. Lung disease was assessed by scoring lung pathology and by measuring soluble collagen levels in lavage fluid. Serum micro ribonucleic acids (miRNAs) were also measured. Inbred sibling pairs of animals demonstrated high coinheritance of the phenotypes of disease susceptibility or disease resistance. The plasma levels of one miRNA were clearly correlated in sibling mice. The results showed that, as in humans, the lines that comprise the Collaborative Cross exhibited wide genetic variation in response to this drug. This finding suggests that the genetically diverse Collaborative Cross animals may reveal drug effects that might be missed if a study were based on a conventional mouse strain.

Keywords: collaborative cross, drug side effects, genetic diversity, disease susceptibility, disease resistance, bleomycin, lung disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Peter Avery, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:79-91

Published Date: 13 September 2009

Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel

Andrew S Bomback, James A Tumlin, Joel Baranski, et al

Drug Design, Development and Therapy 2011, 5:147-153

Published Date: 14 March 2011

Clinical implementation of RNA signatures for pharmacogenomic decision-making

Tang W, Hu Z, Muallem H, Gulley ML

Pharmacogenomics and Personalized Medicine 2011, 4:95-107

Published Date: 8 September 2011

Clinical application of high throughput molecular screening techniques for pharmacogenomics

Wiita AP, Schrijver I

Pharmacogenomics and Personalized Medicine 2011, 4:109-121

Published Date: 8 September 2011

An exploratory study on medications in Qatar homes

Kheir N, El Hajj MS, Wilbur K, Kaissi RML, Yousif A

Drug, Healthcare and Patient Safety 2011, 3:99-106

Published Date: 20 December 2011

Choroidal thinning in high myopia measured by optical coherence tomography

Ikuno Y, Fujimoto S, Jo Y, Asai T, Nishida K

Clinical Ophthalmology 2013, 7:889-893

Published Date: 15 May 2013